Organovo says 3D Liver system distinguished toxic drug in study Organovo announced that an opinion leader reported results from a collaborative study conducted with Organovo scientists using Organovo’s 3D Human Liver Tissues. Dr. Adrian Roth, Head of Mechanistic Safety for Roche Pharmaceutical Research and Early Development at the Roche Innovation Center Basel, presented results from a collaborative study executed by Organovo scientists. The results of the study showed Organovo’s 3D Liver system was able to distinguish a toxic drug known to cause drug induced liver injury from a close chemical analogue that is known to be non-toxic, the company said. "Further, the toxicity of the toxic compound was detected at physiologically relevant doses, an important observation not previously reported with the same compounds in other model liver systems," it added. Organovo said it continues to be on track to launch its upcoming 3D Human Liver Tissue on its previously announced timelines, before the end of 2014.